PMID- 12807526
OWN - NLM
STAT- MEDLINE
DCOM- 20040120
LR  - 20170214
IS  - 0333-1024 (Print)
IS  - 0333-1024 (Linking)
VI  - 23
IP  - 6
DP  - 2003 Jul
TI  - Eletriptan for the treatment of migraine in patients with previous poor response 
      or tolerance to oral sumatriptan.
PG  - 463-71
AB  - To determine the tolerability and efficacy of eletriptan in patients who had 
      discontinued oral sumatriptan due to lack of efficacy or intolerable adverse 
      events (AEs) during previous clinical treatment (not a controlled trial). 
      Eletriptan is a potent, selective 5-HT1B/1D receptor agonist with beneficial 
      pharmacokinetic properties compared with sumatriptan. In a double-blind, parallel 
      group, placebo-controlled multicentre study, patients with and without aura (n = 
      446) were randomized to 40 mg eletriptan (E40, n = 188), 80 mg eletriptan (E80, n 
      = 171) or placebo (n = 87) for treatment of up to three migraine attacks. 
      Two-hour headache response, based on first-dose, first-attack data, was 59% for 
      eletriptan 40 mg, 70% for eletriptan 80 mg, and 30% for placebo (P < 0.0001 for 
      both doses of eletriptan vs. PBO; P < 0.05 for E80 vs. E40). Onset of action was 
      rapid, with 1-h headache response rates significantly superior for E40 and E80 
      vs. placebo (40%, 48%, 15%; P < 0.0005). Both E40 and E80 were significantly 
      superior to placebo, based on first-dose, first-attack data, for 2-h pain-free 
      response (35%, 42%, and 7%; P < 0.0001). Both E40 and E80 demonstrated 
      significant consistency of response, with headache relief rates at 2 h on at 
      least two of three attacks in 66% and 72% vs. 15% on placebo (P < 0.001). AEs 
      were mild to moderate in severity and dose related. The most commonly reported 
      AEs included nausea, vomiting, asthenia, and chest symptoms. E40 and E80 produce 
      an effective response in patients who had previously discontinued treatment with 
      sumatriptan due to lack of efficacy or side-effects.
FAU - Farkkila, M
AU  - Farkkila M
AD  - Helsinki Headache Centre, Helsinki, Finland. markus.farkkila@fimnet.fi
FAU - Olesen, J
AU  - Olesen J
FAU - Dahlof, C
AU  - Dahlof C
FAU - Stovner, L J
AU  - Stovner LJ
FAU - ter Bruggen, J P
AU  - ter Bruggen JP
FAU - Rasmussen, S
AU  - Rasmussen S
FAU - Muirhead, N
AU  - Muirhead N
FAU - Sikes, C
AU  - Sikes C
LA  - eng
PT  - Clinical Trial
PT  - Comparative Study
PT  - Journal Article
PT  - Multicenter Study
PT  - Randomized Controlled Trial
PT  - Research Support, Non-U.S. Gov't
PL  - England
TA  - Cephalalgia
JT  - Cephalalgia : an international journal of headache
JID - 8200710
RN  - 0 (Indoles)
RN  - 0 (Pyrrolidines)
RN  - 0 (Tryptamines)
RN  - 22QOO9B8KI (eletriptan)
RN  - 8R78F6L9VO (Sumatriptan)
SB  - IM
MH  - Administration, Oral
MH  - Adult
MH  - Aged
MH  - Double-Blind Method
MH  - Drug Tolerance/physiology
MH  - Female
MH  - Humans
MH  - Indoles/*therapeutic use
MH  - Male
MH  - Middle Aged
MH  - Migraine Disorders/*drug therapy/physiopathology
MH  - Pyrrolidines/*therapeutic use
MH  - Sumatriptan/*therapeutic use
MH  - Tryptamines
EDAT- 2003/06/17 05:00
MHDA- 2004/01/21 05:00
CRDT- 2003/06/17 05:00
PHST- 2003/06/17 05:00 [pubmed]
PHST- 2004/01/21 05:00 [medline]
PHST- 2003/06/17 05:00 [entrez]
AID - 554 [pii]
AID - 10.1046/j.1468-2982.2003.00554.x [doi]
PST - ppublish
SO  - Cephalalgia. 2003 Jul;23(6):463-71. doi: 10.1046/j.1468-2982.2003.00554.x.